Receptors for the anaphylatoxins C3a and C5a are expressed in human atherosclerotic coronary plaques

被引:80
作者
Oksjoki, Riina
Laine, Petri
Helske, Satu
Kreula, Pirjo Vehmaan
Mayranpaa, Mikko I.
Gasque, Philippe
Kovanen, Petri T.
Pentikainen, Markku O.
机构
[1] Wihuri Res Inst, FIN-00140 Helsinki, Finland
[2] Univ Helsinki Cent Hosp, Dept Med, Div Cardiol, Helsinki, Finland
[3] Cardiff Univ, Dept Med Biochem, Brain Inflammat & Immun Grp, Cardiff, Wales
关键词
atherosclerosis; coronary vessels; complement; anaphylatoxins;
D O I
10.1016/j.atherosclerosis.2006.12.016
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The anaphylatoxins C3a and C5a are potent chemotactic and pro-inflammatory peptides that are released during complement activation, and recent clinical work have suggested them a role in acute coronary events. Here we studied whether human coronary plaques express anaphylatoxin receptors C3aR and C5aR, i.e. whether they have the potential to respond to anaphylatoxins. For this purpose, both normal (n = 14) and atherosclerotic (n = 20) human coronary artery samples were collected for histological and PCR analyses. Immunohistochemistry demonstrated that in atherosclerotic, but not in normal intimas, C3aR and C5aR were present. Consistently, PCR analysis showed that the expression of both receptors was > 5-fold increased in the atherosclerotic plaques (p < 0.01). Double immunofluorescence stainings revealed that in the plaques the principal cells expressing both C3aR and C5aR were macrophages. Moreover, T cells expressed C5aR and a small fraction of them also expressed C3aR, the mast cells expressed C5aR, whereas endothelial cells and subendothelial smooth muscle cells expressed both C3aR and C5aR. In conclusion, the presence of receptors for anaphylatoxins in human coronary plaques suggests that anaphylatoxins activate coronary plaques, and points the complement system as a potential therapeutic target in attempts to stabilize them. (c) 2006 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:90 / 99
页数:10
相关论文
共 35 条
[1]   Distinct tissue site-specific requirements of mast cells and complement components C3/C5a receptor in IgG immune complex-induced injury of skin and lung [J].
Baumann, U ;
Chouchakova, N ;
Gewecke, B ;
Köhl, J ;
Carroll, MC ;
Schmidt, RE ;
Gessner, JE .
JOURNAL OF IMMUNOLOGY, 2001, 167 (02) :1022-1027
[2]   ROLE OF INFLAMMATION IN CORONARY PLAQUE DISRUPTION [J].
BUJA, LM ;
WILLERSON, JT .
CIRCULATION, 1994, 89 (01) :503-505
[3]   Expression cloning of the human C3a anaphylatoxin receptor (C3aR) from differentiated U-937 cells [J].
Crass, T ;
Raffetseder, U ;
Martin, U ;
Grove, M ;
Klos, A ;
Kohl, J ;
Bautsch, W .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1996, 26 (08) :1944-1950
[4]   Continuous 48-h C1-inhibitor treatment, following reperfusion therapy, in patients with acute myocardial infarction [J].
de Zwaan, C ;
Kleine, AH ;
Diris, JHC ;
Glatz, JFC ;
Wellens, HJJ ;
Strengers, PFW ;
Tissing, M ;
Hack, CE ;
van Dieijen-Visser, MP ;
Hermens, WT .
EUROPEAN HEART JOURNAL, 2002, 23 (21) :1670-1677
[5]  
DELBALZO U, 1990, J PHARMACOL EXP THER, V253, P171
[6]  
DELBALZO UH, 1985, P NATL ACAD SCI USA, V82, P886
[7]  
Gasque P, 1998, J IMMUNOL, V160, P3543
[8]  
Gasque P, 1997, AM J PATHOL, V150, P31
[9]   C5a initiates the inflammatory cascade in immune complex peritonitis [J].
Godau, J ;
Heller, T ;
Hawlisch, H ;
Trappe, M ;
Howells, E ;
Best, J ;
Zwirner, J ;
Verbeek, JS ;
Hogarth, PM ;
Gerard, C ;
van Rooijen, N ;
Klos, A ;
Gessner, JE ;
Köhl, J .
JOURNAL OF IMMUNOLOGY, 2004, 173 (05) :3437-3445
[10]   Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction - The COMplement inhibition in myocardial infarction treated with angioplasty (COMMA) trial [J].
Granger, CB ;
Mahaffey, KW ;
Weaver, WD ;
Theroux, P ;
Hochman, JS ;
Filloon, TG ;
Rollins, S ;
Todaro, TG ;
Nicolau, JC ;
Ruzyllo, W ;
Armstrong, PW .
CIRCULATION, 2003, 108 (10) :1184-1190